ATE531822T1 - Diagnose von prostatakrebs - Google Patents

Diagnose von prostatakrebs

Info

Publication number
ATE531822T1
ATE531822T1 AT08701643T AT08701643T ATE531822T1 AT E531822 T1 ATE531822 T1 AT E531822T1 AT 08701643 T AT08701643 T AT 08701643T AT 08701643 T AT08701643 T AT 08701643T AT E531822 T1 ATE531822 T1 AT E531822T1
Authority
AT
Austria
Prior art keywords
prostate cancer
kiaa0153
diagnosis
biological sample
inhibiting
Prior art date
Application number
AT08701643T
Other languages
English (en)
Inventor
Bohdan Wasylyk
Alberto Zambrano
Joseph Abecassis
Helmut Klocker
Jack Schalken
Original Assignee
Centre Nat Rech Scient
Ct Paul Strauss
Univ Louis Pasteur U L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Ct Paul Strauss, Univ Louis Pasteur U L P filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE531822T1 publication Critical patent/ATE531822T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/9015Ligases (6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08701643T 2007-01-23 2008-01-23 Diagnose von prostatakrebs ATE531822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88183007P 2007-01-23 2007-01-23
PCT/EP2008/050761 WO2008090177A2 (en) 2007-01-23 2008-01-23 Diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
ATE531822T1 true ATE531822T1 (de) 2011-11-15

Family

ID=39512588

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08701643T ATE531822T1 (de) 2007-01-23 2008-01-23 Diagnose von prostatakrebs

Country Status (5)

Country Link
US (1) US20110165178A1 (de)
EP (1) EP2126136B1 (de)
AT (1) ATE531822T1 (de)
CA (1) CA2676436A1 (de)
WO (1) WO2008090177A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CA2822530C (en) * 2011-01-21 2023-02-21 Basilea Pharmaceutica Ag Glu-tubulin as a biomarker for furazanobenzimidazoles
FR3016638B1 (fr) * 2014-01-23 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Nouvelle methode de depistage du cancer de la prostate
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
WO2021252747A1 (en) 2020-06-10 2021-12-16 1Ox Genomics, Inc. Fluid delivery methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer

Also Published As

Publication number Publication date
WO2008090177A2 (en) 2008-07-31
US20110165178A1 (en) 2011-07-07
CA2676436A1 (en) 2008-07-31
EP2126136A2 (de) 2009-12-02
WO2008090177A3 (en) 2008-09-18
EP2126136B1 (de) 2011-11-02

Similar Documents

Publication Publication Date Title
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
WO2005084109A3 (en) Cancer specific gene mh15
ATE554389T1 (de) Apex als marker für lungenkrebs
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2007114986A3 (en) Cooperative probes and methods of using them
GB2451042A (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
EP2516681A4 (de) Zusammensetzungen und verfahren zur erkennung kleiner rnas
GB2459228A (en) Exosome-associated microrna as a diagnostic marker
EA201370063A1 (ru) Фосфолипидом рака
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2012024255A3 (en) Camkk-beta as a target for treating cancer
EP2522743A3 (de) Zum Prostatakrebsrisiko beitragende genetische Varianten
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
EA201390638A1 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
MD20130098A2 (ro) Test pentru determinarea lizil oxidazei-2 şi metode de utilizare a acestuia
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
ATE531822T1 (de) Diagnose von prostatakrebs
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal